

1 Article

2 Ectopic Lipid Accumulation is Key Feature in Early 3 Stages of Wooden Breast

4 Juniper A. Lake ¹, Michael B. Papah ² and Behnam Abasht ^{3,*}

5 ¹ Center for Bioinformatics and Computational Biology, University of Delaware, Newark, DE, United States
6 of America; dnovick@udel.edu

7 ² Department of Animal and Food Sciences, University of Delaware, Newark, DE, United States of America;
8 papah@udel.edu

9 ³ Department of Animal and Food Sciences, University of Delaware, Newark, DE, United States of America;
10 abasht@udel.edu

11 * Correspondence: abasht@udel.edu; Tel.: +01-302-831-8876 (B.A.)

12 **Abstract:** Wooden breast is a muscle disorder affecting modern commercial broiler chickens that
13 causes a palpably firm pectoralis major muscle and severe reduction in meat quality. Most studies
14 have focused on advanced stages of wooden breast apparent at market age, resulting in limited
15 insights into the etiology and early pathogenesis of the myopathy. Therefore, the objective of this
16 study was to identify early molecular signals in the wooden breast transcriptional cascade by
17 performing gene expression analysis on the pectoralis major muscle of two-week-old birds that may
18 later exhibit the wooden breast phenotype by market age at 7 weeks. Biopsy samples of the left
19 pectoralis major muscle were collected from a subset of 101 birds randomly selected from a total of
20 302 birds at 14 days of age, after which all birds were raised to 7 weeks of age for scoring of wooden
21 breast. RNA sequencing was performed on 5 unaffected and 8 affected female chicken samples,
22 selected based on wooden breast scores (0 to 4) assigned at necropsy where affected birds had scores
23 of 2 or 3 (mildly or moderately affected) while unaffected birds had scores of 0 (no apparent gross
24 lesions). Differential expression analysis identified 60 genes found to be significant at an FDR-
25 adjusted p value of 0.05. Of these, 26 were previously demonstrated to exhibit altered expression or
26 genetic polymorphisms related to glucose tolerance or diabetes mellitus in mammals. Additionally,
27 9 genes have functions directly related to lipid metabolism and 11 genes are associated with
28 adiposity traits such as intramuscular fat and body mass index. This study suggests that wooden
29 breast disease is first and foremost a metabolic disorder characterized primarily by ectopic lipid
30 accumulation in the pectoralis major.

31 **Keywords:** wooden breast; broilers; myopathy; breast muscle

32

33 1. Introduction

34 Wooden breast is one of several muscle abnormalities of modern commercial broiler chickens
35 that causes substantial economic losses in the poultry industry due to its impact on meat quality.
36 Emerging evidence suggests wooden breast may also be detrimental to bird welfare as affected
37 chickens exhibit increased locomotor difficulties, decreased wing mobility, and higher mortality rates
38 [1–3]. While the etiology of the myopathy is still poorly understood, many believe it to be a side-effect
39 of improved management practices and selective breeding for performance traits due to increased
40 susceptibility among broilers with high feed efficiency [4,5], breast muscle yield [4,6,7], breast muscle
41 thickness [6,8], and growth rate [9,10], including growth rate during the first 1-2 weeks post-hatch
42 [2].

43 Macroscopic manifestations of the disorder include pale and hardened areas, subcutaneous and
44 fascial edema, petechial hemorrhages, spongy areas with disintegrating myofiber bundles, and white
45 fatty striations characteristic of white striping [2,11]. An early study of wooden breast characterized
46 its microscopic presentation as polyphasic myodegeneration and necrosis with regeneration and

47 interstitial connective tissue accumulation (fibrosis), primarily affecting the cranial end of the
48 pectoralis major muscle [11]. However, it has since been demonstrated that venous inflammation
49 (phlebitis) and perivascular lipid and inflammatory cell infiltration appear in the first week of age
50 and precede other symptoms [2]. Differential gene expression analysis of the pectoralis major in 7-
51 week-old broilers suggests that hypoxia, oxidative stress, fiber-type switching, and increased
52 intracellular calcium may be important components of the myopathy [12]. In two- and three-week
53 old birds, differentially expressed genes were mostly associated with increased inflammation,
54 vascular disease, increased oxidative stress, extracellular matrix remodeling, dysregulation of
55 carbohydrates and lipids, and impaired excitation-contraction coupling [13]. Metabolomic profiling
56 is in agreement with these results and provides evidence of oxidative stress and dysregulated
57 carbohydrate and lipid metabolism in affected birds at 7 weeks of age [14].

58 The objective of the present study was to better characterize the transcriptional anomalies that
59 exist in the pectoralis major of two-week-old birds that later develop wooden breast by market age
60 at 7 weeks. Only one other gene expression study has investigated early stages of wooden breast [13].
61 The current study serves as a continuation of that work, but makes two key changes. First, unlike the
62 previous study that used only male birds, we included only female birds in the RNA-seq analysis.
63 Second, birds in the affected group all possessed mild or moderate wooden breast phenotypes rather
64 than severe symptoms, which allowed us to capture a clearer signal of the earliest transcriptomic
65 perturbations.

66 2. Materials and Methods

67 2.1 Experimental Animals and Tissue Collection

68 The University of Delaware Institutional Animal Care and Use Committee approved the animal
69 conditions and experimental procedures used in this scientific study under protocol number 48R-
70 2015-0. For this experiment, 302 mixed male and female Cobb500 broilers were raised according to
71 industry growing standards in two poultry houses from 1 day to 7 weeks of age with free access to
72 feed and water. Biopsy samples of the craniolateral area of the left pectoralis major muscle were
73 collected from 101 randomly selected birds at 14 days of age in the same manner described by a
74 previous study [13]. After biopsy, all birds were grown out to 7 weeks of age, at which time they were
75 euthanized by cervical dislocation. During necropsy, the pectoralis major muscles were evaluated for
76 gross lesions and palpable firmness associated with wooden breast and each bird was assigned a
77 wooden breast score using a 0-4 scale; 0-Normal indicates the bird had no macroscopic signs of the
78 myopathy, 1-Minimal indicates 1% or less of the breast muscle was affected, 2-Mild indicates between
79 1% and 10% of the breast muscle was affected, 3-Moderate indicates between 10% and 50% of the
80 breast muscle was affected, and a score of 4-Severe indicates that more than 50% was affected. This
81 scoring system is slightly different from the one previously used in our laboratory and separates
82 unaffected, mildly and moderately affected chickens with a higher resolution.

83 2.2 Sample Selection and RNA-Sequencing

84 Selection of samples for use in RNA-seq analysis was based on wooden breast scores assigned
85 at necropsy. A total of 6 unaffected and 8 affected birds were identified; affected birds had scores of
86 2 or 3 (mildly or moderately affected) while unaffected birds had scores of 0 (no apparent gross
87 lesions). Only samples taken from female birds were used because there was an insufficient number
88 of male birds that were classified as unaffected. Total RNA was extracted from pectoralis major tissue
89 samples using the mirVana miRNA Isolation Kit (Thermo Fisher Scientific) according to the
90 manufacturer's protocol and stored at -80°C until cDNA library preparation. Each RNA sample was
91 quantified using the NanoDrop 1000 Spectrophotometer (Thermo Fisher scientific) and quality was
92 assessed with the Fragment Analyzer at the Delaware Biotechnology Institute (DBI). cDNA libraries
93 were constructed using the ScriptSeq Complete Kit (Human/Mouse/Rat) (Illumina) with the optional
94 step of adding a user-defined barcode to the library. The 14 barcoded cDNA libraries were
95 normalized and 10 µl of each sample were pooled in two tubes (7 samples in each pool). Pooled

96 libraries were subsequently submitted to the DBI for paired-end 2x76-nucleotide sequencing on two
97 lanes of a flow cell using the HiSeq 2500 Sequencing System (Illumina).

98 Raw sequencing reads were demultiplexed and then checked for quality using FastQC v0.11.7
99 [15]. All samples passed the quality check and were submitted to Trimmomatic v0.38 [16] to trim
100 leading and trailing bases with quality below 20, remove reads with an average quality below 15, and
101 remove reads that were shorter than 30 bases in length. Trimmed reads were then mapped to both
102 Gallus_gallus-5.0 (Ensembl release 94) and GRCg6a (Ensembl release 95) chicken reference genomes
103 using HISAT2 v2.1.0 [17] with concordant mapping required for both reads in each pair. Cuffdiff
104 v2.2.1 [18] was used with the fragment bias correction option to identify differentially expressed
105 genes between affected and unaffected birds. Genes were considered statistically significant if the
106 FDR-adjusted p-value was ≤ 0.05 . The use of two reference genome builds, the latter of which was
107 released during the course of this study, provided validation of our results and allowed us to capture
108 differentially expressed genes that may have borderline statistical significance due to assembly errors
109 or bias. One sample (animal ID 424183) in the unaffected group displayed an extreme outlier
110 expression pattern; it was therefore removed and differential expression analysis with Cuffdiff was
111 repeated without this sample (5 unaffected vs. 8 affected). In order to compile the results generated
112 from each reference genome, Ensembl gene IDs from Gallus-gallus-5.0 were mapped to GRCg6a gene
113 IDs using Ensembl's ID History Converter; differentially expressed genes with annotation differences
114 between the two reference genome releases were scrutinized for consistency. Pairwise correlation
115 analysis and visualization of differentially expressed genes was conducted with the "stats" and
116 "corrplot" packages [19] in R only using expression data generated with the GRCg6a reference
117 genome build.

118 3. Results

119 An average of 19,616,353 paired-end sequence reads were generated per sample, which was
120 reduced to an average of 19,609,044 paired-end reads after trimming. The average mapping rate per
121 sample was 74.5% with the Gallus_gallus-5.0 reference genome build and 75.1% with GRCg6a. The
122 total number of sequenced reads, trimmed reads, and mapped reads per sample can be found in
123 Table S1.

124 There were 52 differentially expressed genes identified using the Gallus_gallus-5.0 reference
125 genome build and 29 differentially expressed genes using the GRCg6a genome build. After
126 accounting for changes in annotation of Ensembl Gene IDs between genome releases, a total of 60
127 genes were found to be differentially expressed between affected and unaffected groups across both
128 analyses, with 18 differentially expressed genes overlapping between both Gallus_gallus-5.0 and
129 GRCg6a. Three Ensembl Gene IDs from the earlier build were deprecated in GRCg6a and were
130 excluded from further analysis. Of the 60 differentially expressed genes used for downstream
131 analysis, 52 were upregulated in affected birds and 8 were downregulated in affected birds (Table 1).

132 **Table 1.** Differentially expressed genes between wooden breast affected pectoralis major muscle
133 samples and unaffected samples at 2 weeks of age. Log2FC is calculated by
134 $\log_2(\text{FPKM}_{\text{affected}}/\text{FPKM}_{\text{unaffected}})$. Unknown gene names are indicated with a dash (-). Non-
135 significant p-values (i.e. FDR-adjusted p-values > 0.05) are indicated as n.s.


Gene ID	Gene Symbol	Gene Name	Log2FC Galgal5	Log2FC GRCg6a
Genes upregulated in affected group				
ENSGALG00000046652	-	-	1.55	n.s.
ENSGALG00000052084	-	-	n.s.	2.06
ENSGALG00000006491	ANKRD1	Ankyrin repeat domain 1	1.28	0.99
ENSGALG00000049422*	ATF3	Activating transcription factor 3	1.04	n.s.
ENSGALG00000009846	BBS5	Bardet-Biedl syndrome 5	0.76	n.s.
ENSGALG00000017040	C4A	Complement C4A (Rodgers blood group)	1.24	0.96
ENSGALG00000008439	CD36	CD36 molecule	0.87	n.s.

ENSGALG00000046316	CFAP97D1	CFAP97 domain containing 1	1.14	n.s.
ENSGALG00000027874	CHAC1	ChaC glutathione specific gamma-glutamylcyclotransferase 1	1.99	n.s.
ENSGALG00000037856	CHL1	Cell adhesion molecule L1 like	1.44	n.s.
ENSGALG00000034500	CIDEA	Cell death-inducing DFFA-like effector a	1.51	1.22
ENSGALG00000012790	DSP	Desmoplakin	1.50	n.s.
ENSGALG00000015876	ELOVL4	ELOVL fatty acid elongase 4	2.19	n.s.
ENSGALG00000001204	ENKD1	Enkurin domain containing 1	2.07	n.s.
ENSGALG00000008563	ENTPD6	Ectonucleoside triphosphate diphosphohydrolase 6	0.80	n.s.
ENSGALG00000037050	FABP3	Fatty acid binding protein 3	0.77	0.72
ENSGALG00000030025	FABP4	Fatty acid binding protein 4	1.74	1.52
ENSGALG00000013100	GRB10	Growth factor receptor bound protein 10	0.77	n.s.
ENSGALG00000011404	HOPX	HOP homeobox	1.19	1.04
ENSGALG00000023818	HSPB9	Heat shock protein family B (small) member 9	1.14	1.13
ENSGALG00000032672	KRT5	Keratin 5	n.s.	1.68
ENSGALG00000016174	LMBRD1	LMBR1 domain containing 1	0.87	n.s.
ENSGALG00000008805	LMOD2	Leiomodin 2	1.39	n.s.
ENSGALG000000021286	LOC427654	Parvalbumin beta-like	2.36	2.36
ENSGALG00000023819	LOC772158	Heat shock protein 30C-like	0.74	0.76
ENSGALG00000015425	LPL	Lipoprotein lipase	0.80	n.s.
ENSGALG00000043582	LY6CLEL	Lymphocyte antigen 6 complex, locus E-like	2.25	n.s.
ENSGALG00000036004	MRPL34	Mitochondrial ribosomal protein L34	n.s.	0.82
ENSGALG00000001709	MUSTN1	Musculoskeletal, embryonic nuclear protein 1	n.s.	1.30
ENSGALG00000012783	MYBPC1	Myosin binding protein C, slow type	1.49	1.17
ENSGALG00000003323	NECAB2	N-terminal EF-hand calcium binding protein 2	n.s.	1.10
ENSGALG00000053246*	OCM2	Oncomodulin 2	0.78	n.s.
ENSGALG00000013414	PDLIM3	PDZ and LIM domain 3	0.75	n.s.
ENSGALG00000027207	PERP2	PERP2, TP53 apoptosis effector	1.29	n.s.
ENSGALG00000004974	PPARG	Peroxisome proliferator-activated receptor gamma	0.89	n.s.
ENSGALG00000040434	RAB18L	Ras-related protein Rab-18-B-like	1.23	1.09
ENSGALG00000043694	RAPGEF4	Rap guanine nucleotide exchange factor 4	1.24	n.s.
ENSGALG00000002637	RBP7	Retinol binding protein 7	1.96	1.65
ENSGALG00000025650	RF00009	Ribonuclease P RNA component H1, 2 pseudogene	n.s.	0.75
ENSGALG00000051839	RF00012	-	n.s.	2.02
ENSGALG00000047347*	RF00017	-	1.38	n.s.
ENSGALG00000025557	RF00030	-	n.s.	0.88
ENSGALG00000054841*	RF0017	-	0.83	1.46
ENSGALG00000005140	RRAD	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	1.63	1.20
ENSGALG00000051456	RTN2	Reticulon 2	n.s.	1.00
ENSGALG00000009400	SLC8A3	Solute carrier family 8 member A3	0.70	n.s.
ENSGALG00000042863	SMIM4	Small integral membrane protein 4	n.s.	0.87
ENSGALG00000019157	SMPX	Small muscle protein X-linked	0.94	n.s.
ENSGALG00000009037	SPTLC3	Serine palmitoyltransferase long chain base subunit 3	2.47	n.s.
ENSGALG00000031117	STK17A	Serine/threonine kinase 17a	0.92	n.s.
ENSGALG00000021231	TMEM254	Transmembrane protein 254	1.05	n.s.
ENSGALG00000014261	UCHL1	Ubiquitin C-terminal hydrolase L1	1.07	0.94
Genes downregulated in affected group				
ENSGALG00000025945*	AVD	Avidin	-1.58	-1.69
ENSGALG00000033932	BF1	MHC BF1 class I	-0.84	n.s.
ENSGALG00000006681	BRSK2	BR serine/threonine kinase 2	-2.50	-2.77
ENSGALG00000032220	ELN	Elastin	n.s.	-1.17
ENSGALG00000035309	HBE	Hemoglobin subunit epsilon	-1.59	n.s.

ENSGALG00000002708	LINGO1	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1	-0.78	-0.77
ENSGALG00000006520	MYH11	Myosin, heavy chain 11, smooth muscle	-0.95	n.s.
ENSGALG00000013045	TUBA8B	Tubulin, alpha 8b	-1.67	n.s.

136 * These genes had annotation differences between Gallus_gallus-5.0 and GRCg6a reference genome assemblies.

137



138

139 **Figure 1.** Correlation analysis of differentially expressed genes. Genes with significantly correlated expression
 140 (p value ≤ 0.05) are shown in blue (positive correlation) and red (negative correlation). Two major clusters of
 141 genes have Pearson's correlation coefficients greater than 0.8 for all gene pairs. Cluster 1 consists of 8 genes, all
 142 of which were excluded from further analysis due to presumed skin contamination. Cluster 2 consists of 9
 143 genes related to lipid metabolism or adiposity traits.

144 Correlation analysis of differentially expressed genes revealed two major clusters with Pearson's
 145 correlation coefficients greater than 0.8 for all gene pairs (see Figure 1). The first is a cluster of 8 genes,
 146 all of which were excluded from further analysis due to presumed skin contamination. These include
 147 *serine palmitoyltransferase long chain base subunit 3 (SPTLC3)*, *desmoplakin (DSP)*, *ELOVL fatty acid*
 148 *elongase 4 (ELOVL4)*, *PERP2*, *TP53 apoptosis effector (PERP2)*, *keratin 5 (KRT5)*, *cell adhesion molecule L1*
 149 *like (CHL1)*, *lymphocyte antigen 6 complex, locus E-like (LY6CLEL)*, and *transmembrane protein 254*
 150 *(TMEM254)*. Several of these genes are known to be primarily expressed in the skin and a previous
 151 biopsy study using the same technique demonstrated that biopsy samples are prone to skin

152 contamination [13]. Additionally, differential expression of these genes was driven by the same three
 153 samples, one unaffected and two affected, and expression in the remaining samples was relatively
 154 very low or approximately zero. The second cluster consisted of 9 protein-coding genes with
 155 demonstrated or putative involvement in lipid metabolism. Although no other clusters were
 156 apparent from correlation analysis, functional groupings of differentially expressed genes included
 157 muscle growth and function, calcium signaling, and endoplasmic reticulum stress response. We also
 158 found a substantial number of genes that are differentially expressed, implicated, or otherwise
 159 involved in metabolic syndrome in mammals, which is characterized primarily by diabetes, insulin
 160 resistance, obesity, elevated blood lipids, and high blood pressure.

161 4. Discussion

162 Metabolic syndrome refers to a cluster of conditions, such as obesity, high blood sugar, high
 163 serum triglycerides, low serum HDL cholesterol, and high blood pressure, that put an individual at
 164 greater risk of developing type 2 diabetes, atherosclerosis, cardiomyopathy, non-alcoholic fatty liver
 165 disease, diabetic nephropathy, and other related disorders. Our data revealed a surprising number
 166 of differentially expressed genes implicated in or associated with metabolic syndrome in humans.
 167 Among the 60 differentially expressed genes identified in this study, 19 are previously reported to
 168 exhibit altered expression in relation to diabetes or a closely related metabolic condition and 10 genes
 169 have been identified as candidate genes in association studies of glucose tolerance or diabetes
 170 mellitus (Table 2). Two of these candidate genes are associated with diseases that strongly predispose
 171 individuals to diabetes and other metabolic complications: a deletion in the elastin gene (ELN) is
 172 associated with Williams-Beuren syndrome [20] and mutations in Bardet-Biedl syndrome 5 (BBS5)
 173 are associated with Bardet-Biedl Syndrome [21]. Upon further examination, we found that many of
 174 the conditions surrounding metabolic syndrome in humans possessed important similarities to the
 175 wooden breast phenotype, namely inflammation, ectopic fat deposition, dysregulation of Ca²⁺
 176 homeostasis, endoplasmic reticulum stress, oxidative stress, altered glucose metabolism, fibrosis, and
 177 hypertrophy.

178 **Table 2. Differentially expressed genes linked to diabetes and glucose tolerance.** Of the 60
 179 differentially expressed genes identified in this study, 26 are either proposed as candidate genes for
 180 glucose tolerance or diabetes mellitus or exhibit altered expression in relation to diabetes or a closely
 181 related metabolic condition.

Gene Symbol	Gene Name	Connection	Sources
ATF3	Activating transcription factor 3	Expression	[22]
BBS5	Bardet-Biedl syndrome 5	Genetic variant	[21]
BF1	MHC BF1 class I	Expression	[23]
BRSK2	BR serine/threonine kinase 2	Expression	[24]
C4A	Complement C4A (Rodgers blood group)	Expression	[25]
C4A	Complement C4A (Rodgers blood group)	Genetic variant	[24]
CD36	CD36 molecule	Expression	[26,27]
CIDEA	Cell death-inducing DFFA-like effector a	Expression	[28]
ELN	Elastin	Genetic variant	[20]
ENTPD6	Ectonucleoside triphosphate diphosphohydrolase 6 (putative)	Genetic variant	[29]
FABP3	Fatty acid binding protein 3	Expression	[30]
FABP4	Fatty acid binding protein 4	Expression	[30–32]
GRB10	Growth factor receptor bound protein 10	Expression	[33,34]
LINGO1	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1	Genetic variant	[35,36]
LMBRD1	LMBR1 domain containing 1	Expression	[27]
LMOD2	Leiomodin 2	Genetic variant	[37]
LPL	Lipoprotein lipase	Expression	[32,38]
LPL	Lipoprotein lipase	Genetic variant	[39]
MRPL34	Mitochondrial ribosomal protein L34	Expression	[40,41]

MYH11	Myosin, heavy chain 11, smooth muscle	Expression	[26]
PDLIM3	PDZ and LIM domain 3	Genetic variant	[37]
PPARG	Peroxisome proliferator-activated receptor gamma	Expression	[32,42]
PPARG	Peroxisome proliferator-activated receptor gamma	Genetic variant	[43–47]
RAB18L	Ras-related protein Rab-18-B-like	Expression	[48]
RAPGEF4	Rap guanine nucleotide exchange factor 4	Expression	[49]
RBP7	Retinol binding protein 7	Expression	[50]
RRAD	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Expression	[26]
RTN2	Reticulon 2	Genetic variant	[24]
UCHL1	Ubiquitin C-terminal hydrolase L1	Expression	[51]

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

One of the most compelling links to metabolic syndrome in our data is *RRAD*, *ras related glycolysis inhibitor and calcium channel regulator (RRAD)*, a gene originally named *Ras-related associated with diabetes* because it was identified via subtraction cloning as the only gene out of 4000 cDNA clones that was overexpressed in skeletal muscle of type 2 diabetic individuals compared to non-diabetic or type 1 diabetic individuals [26]. *RRAD* is a small GTPase that binds directly to Ca^{2+} channel beta subunits to regulate intracellular Ca^{2+} signaling in muscle cells [52] and may also have regulatory functions via its interaction with calmodulin [53]. Overexpression of *RRAD* in cultured myocytes was found to reduce insulin-stimulated glucose uptake by 50-90%, which the authors speculated was due to a decrease in intrinsic activity of glucose transporter 4, the insulin-dependent glucose transporter [54]. An in vivo study of transgenic mice overexpressing *RRAD* in skeletal muscle found that high fat feeding produced not only insulin resistance in transgenic mice, but also increased triglyceride metabolism compared to controls [55]. This suggests that *RRAD* may inhibit glycolysis independently from its action on glucose transporters via substrate competition [56]. Another regulator of intracellular Ca^{2+} , *RAPGEF4*, upregulated in the current study, is the direct target of some anti-diabetic drugs called sulfonylureas [49]. The role of Ca^{2+} in metabolic syndrome is complex and not fully understood, but one theory suggests that the disruption of Ca^{2+} homeostasis is a feed-forward pathological cycle resulting from endoplasmic reticulum dysfunction during chronic exposure to excessive nutrients and energy [57].

Endoplasmic reticulum stress in affected birds is supported in our study by the upregulation of *activating transcription factor 3 (ATF3)*, *ChaC glutathione specific gamma-glutamylcyclotransferase 1 (CHAC1)*, and *reticulon 2 (RTN2)* and the downregulation of *BR serine/threonine kinase 2 (BRSK2)*. *ATF3*, *CHAC1*, and *BRSK2* are part of the unfolded protein response [58,59], a highly conserved cellular stress response caused by an accumulation of unfolded or misfolded proteins in the endoplasmic reticulum [60]. An association between the unfolded protein response, lipid metabolism, and metabolic syndrome has been clearly established, but the direction of causality is controversial [61–64]. The role of *ATF3* in particular has been studied in the context of type 2 diabetes, non-alcoholic fatty liver disease, diabetic cardiomyopathy, atherosclerosis, and obesity, with some authors suggesting it may have both detrimental and beneficial functions related to insulin resistance, mitochondrial dysfunction, and inflammation in response to high fat diets [22,65–71]. In arterial endothelial cells, *ATF3* expression can be induced by exposure to high levels of triglyceride-rich lipoprotein lipolysis products [66], substantiating it as a link between high lipid metabolism and cellular stress response.

Ectopic lipid deposition and the resulting lipotoxicity are considered to be a major cause of metabolic syndrome with the precise location of ectopic lipid accumulation dictating specific complications such as atherosclerosis, hepatic steatosis, and diabetic nephropathy [72]. Our results strongly support increased lipid metabolism in the pectoralis major of affected birds. Many of the differentially expressed genes from our analysis encode proteins with critical or rate-limiting functions in lipid metabolism and homeostasis such as lipoprotein triglyceride hydrolysis, fatty acid transport, and lipid droplet regulation. These genes include *lipoprotein lipase (LPL)*, *CD36 molecule (CD36)*, *peroxisome proliferator-activated receptor gamma (PPARG)*, *retinol binding protein 7 (RBP7)*, *fatty acid binding protein 3 (FABP3)*, *fatty acid binding protein 4 (FABP4)*, *cell death-inducing DFFA-like effector a (CIDEA)*, *ras-related protein Rab-18-B-like (RAB18L)*, and *LMBR1 domain containing 1 (LMBRD1)*

225 [31,48,73–81]. Several other genes, some of which are functionally uncharacterized or poorly
226 understood with regard to lipid metabolism, have expression or genetic polymorphisms correlated
227 with adiposity traits such as body mass index, percent intramuscular fat, percent abdominal fat, or
228 blood lipid levels. These genes include *HOP homeobox (HOPX)*, *myosin binding protein C, slow type*
229 *(MYBPC1)*, and *Bardet-Biedl syndrome 5 (BBS5)*, *growth factor receptor bound protein 10 (GRB10)*, *CFAP97*
230 *domain containing 1 (CFAP97D1)*, *hemoglobin subunit epsilon (HBE)*, *ectonucleoside triphosphate*
231 *diphosphohydrolase 6 (ENTPD6)*, *complement C4A (Rodgers blood group) (C4A)*, *mitochondrial ribosomal*
232 *protein L34 (MRPL34)*, *ATF3*, and *CHAC1* [67,82–95]. This evidence of increased lipid metabolism and
233 fat deposition in the pectoralis major is consistent with histological examinations of 2-week-old birds
234 with wooden breast, in which lipid infiltration and accumulation was established as one of the first
235 signs of disease [2].

236 A large cluster of upregulated genes related to lipid metabolism from the present study were
237 found to exhibit highly correlated expression with Pearson's correlation coefficients greater than 0.8
238 for all gene pairs (see Figure 1). We believe this cluster may represent a functional group as it includes
239 the transcription factor *PPAR γ* and several of its experimentally validated transcriptional targets
240 (*CD36*, *C4A*, *RBP7*, *FABP4*, *CIDEA*, and *LPL*) [77,78,82,96,97]. Upregulation of *PPAR γ* in the early
241 stages of wooden breast is especially important because, as a master regulator of adipogenesis, it is a
242 critical component in governing the distribution of lipid deposition in the body and the development
243 of various metabolic conditions [98–102]. It is also one of the few established genes that has been
244 associated with common forms of type 2 diabetes across multiple genome-wide association studies
245 [43–47]. While *PPAR γ* is mainly associated with adipose tissue [97], it possesses important functions
246 in skeletal muscle and other tissues. A knockout study in mice found that *PPAR γ* is not only critical
247 for fat infiltration during skeletal muscle regeneration, but that it is required for muscle stem cell
248 function and efficient muscle repair due to crosstalk with two myogenic transcription factors,
249 myogenic differentiation 1 (*MYOD1*) and paired box 7 (*PAX7*) [103]. In skeletal muscle of broiler
250 chickens and other meat-type animals, increased expression of *PPARG* and *PPAR γ* target genes is
251 frequently associated with higher intramuscular fat content [104–107].

252 Several genes involved in myogenic differentiation and muscle hypertrophy are upregulated in
253 affected birds: *musculoskeletal, embryonic nuclear protein 1 (MUSTN1)*, *ankyrin repeat domain 1*
254 *(ANKRD1)*, and *HOPX* have roles in myotube formation, myofusion, and regulation of other
255 myoblast differentiation genes [85,108–112], although studies of *HOPX* in chickens have found that
256 it's highly expressed in adipose tissue and has functions related to adipocyte differentiation [84,85].
257 Other upregulated genes related to development and regeneration of the musculoskeletal system
258 include *PDZ and LIM domain 3 (PDLIM3)*, *small muscle protein X-linked (SMPX)*, and *leiomodlin 2*
259 *(LMOD2)*. Two of these, *SMPX* and *PDLIM3*, encode Z-disc associated proteins with putative
260 mechanosensory or stretch signaling roles in striated muscle [113,114]. Expression of *MUSTN1*,
261 *ANKRD1*, *PDLIM3*, and *SMPX* can be induced by eccentric contraction exercises [115–117] or passive
262 stretch [118], suggesting a role in muscle hypertrophy and repair [114]. Upregulation of genes related
263 to hypertrophy in affected birds is in line with higher breast muscle yield in affected birds [4,6,7]. In
264 fact, speculation on the cause of wooden breast and related muscle disorders has focused largely on
265 impaired oxygen supply and buildup of metabolic waste resulting from sustained rapid growth of
266 the pectoralis major [8,119–121]. However, upregulation of these genes may also be part of the disease
267 progression. If wooden breast is a metabolic disorder with similarities to diabetes, e.g. in
268 dysregulation of intracellular calcium homeostasis [12,13] and intracellular glucose metabolism [14],
269 excessive growth of the pectoralis major in affected chickens might be, at least in part, a symptom of
270 the disease rather than solely a predisposing factor. Although diabetes generally causes skeletal
271 muscle atrophy, various complications of diabetes such as cardiomyopathy, non-alcoholic fatty liver
272 disease, and diabetic nephropathy can cause structural remodeling that includes hypertrophy and
273 even fibrosis of the of the heart, liver, and kidneys respectively [122–124].

274 Interestingly, our data showed upregulation of several genes, such as *MYBPC1* and *SMPX*
275 [125,126], that are more closely associated with slow-twitch oxidative muscle rather than fast-twitch
276 glycolytic muscle. For example, *LMOD2* has been alternatively called cardiac leiomodlin and its levels

277 in cardiac muscle are directly linked to the length of actin-containing thin filaments due to
278 competition for binding with tropomodulin-1 [127]. Overexpression of *LMOD2* in the heart results in
279 elongation of thin filaments and reduced cardiac function as proper thin filament length is necessary
280 to generate contractile force [127,128]. Similarly, *ANKRD1* was previously named cardiac ankyrin
281 repeat protein (CARP) and has been proposed as a marker of cardiac hypertrophy due to its increased
282 expression in 3 distinct models of cardiac hypertrophy in rats [129]. The lipid transporter *FABP3*,
283 which is involved in the uptake, intracellular metabolism and transport of long-chain fatty acids, is
284 most abundantly expressed in slow-twitch skeletal and cardiac muscle of humans [93]. Upregulation
285 of these genes is consistent with previous reports of fiber-type switching in 7-week-old birds with
286 wooden breast [12] and may suggest that the pectoralis major muscle of affected birds resembles
287 cardiac or slow-twitch muscle at the transcriptional level despite the metabolic limitations of
288 glycolytic muscle fibers.

289 5. Conclusions

290 The findings of this study show that transcriptional changes associated with early stages of
291 wooden breast disease in 2-week-old birds have significant overlap with genes that are dysregulated
292 in metabolic syndrome in humans. Although the underlying causes of metabolic dysfunction
293 possibly leading to pathological progression of the disease remain unknown, this study clearly
294 demonstrates that early upregulation of lipid metabolism in the pectoralis major is a key feature of
295 the myopathy. Affected birds also show dysregulation of various genes involved in muscle growth
296 and function as well as calcium signaling and endoplasmic reticulum stress. Our results are consistent
297 with previous reports of metabolic perturbations in wooden breast [12–14], especially a recent study
298 suggesting that the increased ability to direct alimentary resources, particularly fatty acids, to the
299 pectoralis major muscle may underlie susceptibility to wooden breast [5]. Additional studies are
300 needed to understand the mechanisms underlying this metabolic dysfunction and to investigate the
301 possible link between wooden breast and metabolic syndrome.

302 **Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Table S1: Sequencing
303 and mapping statistics for RNA-Seq analysis of 8 wooden breast affected and 6 unaffected pectoralis major
304 muscle samples.

305 **Author Contributions:** Conceptualization, Juniper A. Lake and Behnam Abasht; Formal analysis, Juniper A.
306 Lake; Funding acquisition, Behnam Abasht; Investigation, Juniper A. Lake and Behnam Abasht; Methodology,
307 Juniper A. Lake, Michael B. Papah and Behnam Abasht; Project administration, Behnam Abasht; Resources,
308 Behnam Abasht; Software, Juniper A. Lake; Supervision, Behnam Abasht; Validation, Juniper A. Lake and
309 Behnam Abasht; Visualization, Juniper A. Lake; Writing – original draft, Juniper A. Lake; Writing – review &
310 editing, Michael B. Papah and Behnam Abasht.

311 **Funding:** This research was funded by the U.S. Department of Agriculture, Agriculture and Food Research
312 Initiative competitive grant number 2016-67015-25027.

313 **Acknowledgments:** The authors gratefully acknowledge the in-kind support by Cobb-Vantress Inc. in providing
314 chicks and chicken feed for this experiment. We also greatly appreciate assistance with samples and data
315 collection from many graduate and undergraduate students at the University of Delaware Department of
316 Animal and Food Sciences. We would like to acknowledge the support from the University of Delaware Center
317 for Bioinformatics and Computational Biology for utilization of their cluster BioMix, which was made possible
318 through support from the Delaware INBRE (NIH GM103446), the state of Delaware and the Delaware
319 Biotechnology Institute (DBI). RNA sequencing services at DBI are greatly appreciated.

320 **Conflicts of Interest:** The authors declare no conflict of interest.

321 References

- 322 1. Gall, S.; Suyemoto, M.M.; Sather, H.M.L.; Sharpton, A.R.; Barnes, H.J.; Borst, L.B. Wooden breast in
323 commercial broilers associated with mortality, dorsal recumbency, and pulmonary disease. *Avian Dis.*
324 *In-Press* 2019.

- 325 2. Papah, M.B.; Brannick, E.M.; Schmidt, C.J.; Abasht, B. Evidence and role of phlebitis and lipid infiltration
326 in the onset and pathogenesis of Wooden Breast Disease in modern broiler chickens. *Avian Pathol.* **2017**,
327 *46*, 623–643.
- 328 3. Norring, M.; Valros, A.; Valaja, J.; Sihvo, H.; Immonen, K.; Puolanne, E. Wooden breast myopathy links
329 with poorer gait in broiler chickens. *Animal* **2018**, 1–6.
- 330 4. Mutryn, M.F.; Fu, W.; Abasht, B. Incidence of Wooden Breast Disease and its correlation with broiler
331 performance and ultimate pH of breast muscle. In Proceedings of the Proceedings of XXII European
332 Symposium on Poultry Meat Quality; Nantes, France, 2015.
- 333 5. Abasht, B.; Zhou, N.; Lee, W.R.; Zhuo, Z.; Peripolli, E. The metabolic characteristics of susceptibility to
334 wooden breast disease in chickens with high feed efficiency. *Poult. Sci.* **2019**, 1–11.
- 335 6. Dalle Zotte, A.; Cecchinato, M.; Quartesan, A.; Bradanovic, J.; Puolanne, E. How does “Wooden Breast”
336 myodegradation affect poultry meat quality? In Proceedings of the 60th International Congress of Meat
337 Science and Technology; Punta Del Este, Uruguay, 2014.
- 338 7. Bailey, R.A.; Watson, K.A.; Bilgili, S.F.; Avendano, S. The genetic basis of pectoralis major myopathies
339 in modern broiler chicken lines. *Poult. Sci.* **2015**, *94*, 2870–2879.
- 340 8. Mudalal, S.; Lorenzi, M.; Soglia, F.; Cavani, C.; Petracci, M. Implications of white striping and wooden
341 breast abnormalities on quality traits of raw and marinated chicken meat. *Animal* **2015**, *9*, 728–734.
- 342 9. Trocino, A.; Piccirillo, A.; Birolo, M.; Radaelli, G.; Bertotto, D.; Filiou, E.; Petracci, M.; Xiccato, G. Effect
343 of genotype, gender and feed restriction on growth, meat quality and the occurrence of white striping
344 and wooden breast in broiler chickens. *Poult. Sci.* **2015**, *94*, 2996–3004.
- 345 10. Livingston, M.L.; Ferket, P.R.; Brake, J.; Livingston, K.A. Dietary amino acids under hypoxic conditions
346 exacerbates muscle myopathies including wooden breast and white stripping. *Poult. Sci.* **2019**, *98*, 1517–
347 1527.
- 348 11. Sihvo, H.K.; Immonen, K.; Puolanne, E. Myodegeneration with fibrosis and regeneration in the
349 pectoralis major muscle of broilers. *Vet. Pathol.* **2014**, *51*, 619–623.
- 350 12. Mutryn, M.F.; Brannick, E.M.; Fu, W.; Lee, W.R.; Abasht, B. Characterization of a novel chicken muscle
351 disorder through differential gene expression and pathway analysis using RNA-sequencing. *BMC*
352 *Genomics* **2015**, *16*, 1–19.
- 353 13. Papah, M.B.; Brannick, E.M.; Schmidt, C.J.; Abasht, B. Gene expression profiling of the early
354 pathogenesis of wooden breast disease in commercial broiler chickens using RNA-sequencing. *PLoS One*
355 **2018**, *13*, e0207346.
- 356 14. Abasht, B.; Mutryn, M.F.; Michalek, R.D.; Lee, W.R. Oxidative stress and metabolic perturbations in
357 wooden breast disorder in chickens. *PLoS One* **2016**, *11*, 1–16.
- 358 15. FastQC Available online: <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
- 359 16. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data.
360 *Bioinformatics* **2014**, *30*, 2114–2120.
- 361 17. Kim, D.; Langmead, B.; Salzberg, S.L. HISAT: A fast spliced aligner with low memory requirements. *Nat.*
362 *Methods* **2015**, *12*, 357–360.
- 363 18. Trapnell, C.; Hendrickson, D.G.; Sauvageau, M.; Goff, L.; Rinn, J.L.; Pachter, L. Differential analysis of
364 gene regulation at transcript resolution with RNA-seq. *Nat. Biotechnol.* **2013**, *31*, 46–53.
- 365 19. Wei, T.; Simko, V. R package “corrplot”: Visualization of a correlation matrix (Version 0.84) 2017.
- 366 20. DeMarsilis, A.J.; Walji, T.A.; Maedeker, J.A.; Stoka, K. V.; Kozel, B.A.; Mecham, R.P.; Wagenseil, J.E.;
367 Craft, C.S. Elastin insufficiency predisposes mice to impaired glucose metabolism. *J. Mol. Genet. Med.*

- 368 2014, 8, 1247–1262.
- 369 21. Beales, P.L.; Elcioglu, N.; Woolf, A.S.; Parker, D.; Flinter, F.A. New criteria for improved diagnosis of
370 Bardet-Biedl syndrome: results of a population survey. *J. Med. Genet.* **1999**, *36*, 437–46.
- 371 22. Qi, L.; Saberi, M.; Zmuda, E.; Wang, Y.; Altarejos, J.; Zhang, X.; Dentin, R.; Hedrick, S.; Bandyopadhyay,
372 G.; Hai, T.; et al. Adipocyte CREB promotes insulin resistance in obesity. *Cell Metab.* **2009**, *9*, 277–286.
- 373 23. Faustman, D.; Li, X.; Lin, H.Y.; Fu, Y.; Eisenbarth, G.; Avruch, J.; Guo, J. Linkage of faulty major
374 histocompatibility complex class I to autoimmune diabetes. *Science (80-.)*. **1991**, *254*, 1756–1761.
- 375 24. Caplen, N.J.; Patel, A.; Millward, A.; Campbell, R.D.; Ratanachaiyavong, S.; Wong, F.S.; Demaine, A.G.
376 Complement C4 and heat shock protein 70 (HSP70) genotypes and type I diabetes mellitus.
377 *Immunogenetics* **1990**, *32*, 427–430.
- 378 25. Lappas, M. Lower circulating levels of complement split proteins C3a and C4a in maternal plasma of
379 women with gestational diabetes mellitus. *Diabet. Med.* **2011**, *28*, 906–911.
- 380 26. Reynet, C.; Kahn, C.R. Rad: A member of the Ras family overexpressed in muscle of type II diabetic
381 humans. *Science (80-.)*. **1993**, *262*, 1441.
- 382 27. Tan, A.L.M.; Langley, S.R.; Tan, C.F.; Chai, J.F.; Khoo, C.M.; Leow, M.K.S.; Khoo, E.Y.H.; Moreno-Moral,
383 A.; Pravenec, M.; Rotival, M.; et al. Ethnicity-specific skeletal muscle transcriptional signatures and their
384 relevance to insulin resistance in Singapore. *J. Clin. Endocrinol. Metab.* **2018**, *104*, 465–486.
- 385 28. Zhou, L.; Xu, L.; Ye, J.; Li, D.; Wang, W.; Li, X.; Wu, L.; Wang, H.; Guan, F.; Li, P. Cidea promotes hepatic
386 steatosis by sensing dietary fatty acids. *Hepatology* **2012**, *56*, 95–107.
- 387 29. Rich, S.S.; Goodarzi, M.O.; Palmer, N.D.; Langefeld, C.D.; Ziegler, J.; Haffner, S.M.; Bryer-Ash, M.;
388 Norris, J.M.; Taylor, K.D.; Haritunians, T.; et al. A genome-wide association scan for acute insulin
389 response to glucose in Hispanic-Americans: The Insulin Resistance Atherosclerosis Family Study (IRAS
390 FS). *Diabetologia* **2009**, *52*, 1326–1333.
- 391 30. Husi, H.; Van Agtmael, T.; Mullen, W.; Bahlmann, F.H.; Schanstra, J.P.; Vlahou, A.; Delles, C.; Perco, P.;
392 Mischak, H. Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes
393 in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. *Circ.*
394 *Cardiovasc. Genet.* **2014**, *7*, 161–170.
- 395 31. Furuhashi, M.; Saitoh, S.; Shimamoto, K.; Miura, T. Fatty acid-binding protein 4 (FABP4):
396 Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases.
397 *Clin. Med. Insights Cardiol.* **2014**, *2014*, 23–33.
- 398 32. Westerbacka, J.; Kolak, M.; Kiviluoto, T.; Arkkila, P.; Sire, J.; Hamsten, A.; Fisher, R.M.; Yki-ja, H. Genes
399 involved in fatty acid partitioning and binding, inflammation are overexpressed in the human fatty liver
400 of insulin-resistant subjects. *Diabetes* **2007**, *56*, 2759–2765.
- 401 33. Lim, M.A.; Riedel, H.; Liu, F. Grb10: more than a simple adaptor protein. *Front. Biosci.* **2007**, *9*, 387–403.
- 402 34. Yang, S.; Deng, H.; Zhang, Q.; Xie, J.; Zeng, H.; Jin, X.; Ling, Z.; Shan, Q.; Liu, M.; Ma, Y.; et al.
403 Amelioration of diabetic mouse nephropathy by catalpol correlates with down-regulation of Grb10 and
404 activation of insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling. *PLoS One* **2016**,
405 *11*, e0151857.
- 406 35. Abdullah, N.; Abdul Murad, N.A.; Attia, J.; Oldmeadow, C.; Mohd Haniff, E.A.; Syafruddin, S.E.; Abd
407 Jalal, N.; Ismail, N.; Ishak, M.; Jamal, R.; et al. Characterizing the genetic risk for Type 2 diabetes in a
408 Malaysian multi-ethnic cohort. *Diabet. Med.* **2015**, *32*, 1377–1384.
- 409 36. Morris, A.D.P.; Voight, B.F.; Teslovich, T.M.; Ferreira, T.; Segre, A. V.; Steinthorsdottir, V.; Strawbridge,
410 R.J.; Khan, H.; Grallert, H.; Mahajan, A.; et al. Large-scale association analysis provides insights into the

- 411 genetic architecture and pathophysiology of type 2 diabetes. *Nat. Genet.* **2012**, *44*, 981–990.
- 412 37. Kang, H.P.; Yang, X.; Chen, R.; Zhang, B.; Corona, E.; Schadt, E.E.; Butte, A.J. Integration of disease-
413 specific single nucleotide polymorphisms, Expression quantitative trait loci and coexpression networks
414 reveal novel candidate genes for type 2 diabetes. *Diabetologia* **2012**, *55*, 2205–2213.
- 415 38. Howard, B. V. Lipoprotein metabolism in diabetes mellitus. *J. Lipid Res.* **1987**, *28*, 613–628.
- 416 39. Yang, T.; Pang, C.P.; Tsang, M.W.; Lam, C.W.; Poon, P.M.K.; Chan, L.Y.S.; Wu, X.Q.; Tomlinson, B.;
417 Baum, L. Pathogenic mutations of the lipoprotein lipase gene in Chinese patients with
418 hypertriglyceridemic type 2 diabetes. *Hum. Mutat.* **2003**, *21*, 453.
- 419 40. Park, P.J.; Kong, S.W.; Tebaldi, T.; Lai, W.R.; Kasif, S.; Kohane, I.S. Integration of heterogeneous
420 expression data sets extends the role of the retinol pathway in diabetes and insulin resistance.
421 *Bioinformatics* **2009**, *25*, 3121–3127.
- 422 41. Moreno-Viedma, V.; Amor, M.; Sarabi, A.; Bilban, M.; Staffler, G.; Zeyda, M.; Stulnig, T.M. Common
423 dysregulated pathways in obese adipose tissue and atherosclerosis. *Cardiovasc. Diabetol.* **2016**, *15*, 1–12.
- 424 42. Park, K.S.; Ciaraldi, T.P.; Abrams-carter, L.; Mudaliar, S.; Nikoulina, S.E.; Henry, R.R. PPAR- γ gene
425 expression is elevated in skeletal muscle of obese and type II diabetic subjects. *Diabetes* **1997**, *46*, 1230–
426 1234.
- 427 43. Zeggini, E.; Scott, L.J.; Saxena, R.; Voight, B.F. Meta-analysis of genome-wide association data and large-
428 scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat. Genet.* **2008**, *40*, 638–645.
- 429 44. Scott, L.J.; Mohlke, K.L.; Bonnycastle, L.L.; Willer, C.J.; Li, Y.; Duren, W.L.; Erdos, M.R.; Stringham, H.M.;
430 Chines, P.S.; Jackson, A.U.; et al. A genome-wide association study of type 2 diabetes in finns detects
431 multiple susceptibility variants. *Science (80-.)*. **2007**, *316*, 1341–1345.
- 432 45. Sanghera, D.K.; Blackett, P.R. Type 2 diabetes genetics: Beyond GWAS. *J. Diabetes Metab.* **2012**, *3*, 6948.
- 433 46. Sladek, R.; Rocheleau, G.; Rung, J.; Dina, C.; Shen, L.; Serre, D.; Boutin, P.; Vincent, D.; Belisle, A.;
434 Hadjadj, S.; et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature*
435 **2007**, *445*, 881–885.
- 436 47. Stumvoll, M.; Häring, H. The peroxisome proliferator-activated receptor- γ 2 Pro12Ala
437 polymorphism. *Diabetes* **2002**, *51*, 2341–2347.
- 438 48. Pulido, M.R.; Diaz-Ruiz, A.; Jiménez-Gómez, Y.; Garcia-Navarro, S.; Gracia-Navarro, F.; Tinahones, F.;
439 López-Miranda, J.; Frühbeck, G.; Vázquez-Martínez, R.; Malagón, M.M. Rab18 dynamics in adipocytes
440 in relation to lipogenesis, lipolysis and obesity. *PLoS One* **2011**, *6*.
- 441 49. Zhang, C.-L.; Katoh, M.; Shibasaki, T.; Minami, K.; Sunaga, Y.; Takahashi, H.; Yokoi, N.; Iwasaki, M.;
442 Miki, T.; Susumu, S. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. *Science*
443 **2009**, *325*, 607–610.
- 444 50. Nie, J.; DuBois, D.C.; Xue, B.; Jusko, W.J.; Almon, R.R. Effects of high-fat feeding on skeletal muscle gene
445 expression in diabetic Goto-Kakizaki rats. *Gene Regul. Syst. Bio.* **2017**, *11*, 1–11.
- 446 51. Zhang, H.; Luo, W.; Sun, Y.; Qiao, Y.; Zhang, L.; Zhao, Z.; Lv, S. Wnt/ β -catenin signaling mediated-UCH-
447 L1 expression in podocytes of diabetic nephropathy. *Int. J. Mol. Sci.* **2016**, *17*.
- 448 52. Finlin, B.S.; Crump, S.M.; Satin, J.; Andres, D.A. Regulation of voltage-gated calcium channel activity by
449 the Rem and Rad GTPases. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100*, 14469–74.
- 450 53. Moyers, J.S.; Bilan, P.J.; Zhu, J.; Kahn, C.R. Rad and Rad-related GTPases interact with calmodulin and
451 calmodulin- dependent protein kinase II. *J. Biol. Chem.* **1997**, *272*, 11832–11839.
- 452 54. Moyers, J.S.; Bilan, P.J.; Reynet, C.; Ronald Kahn, C. Overexpression of Rad inhibits glucose uptake in
453 cultured muscle and fat cells. *J. Biol. Chem.* **1996**, *271*, 23111–23116.

- 454 55. Ilany, J.; Bilan, P.J.; Kapur, S.; Caldwell, J.S.; Patti, M.-E.; Marette, A.; Kahn, C.R. Overexpression of Rad
455 in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma
456 triglyceride level. *Proc. Natl. Acad. Sci.* **2006**, *103*, 4481–4486.
- 457 56. Randle, P.J.; Priestman, D.A.; Mistry, S.C.; Halsall, A. Glucose fatty acid interactions and the regulation
458 of glucose disposal. *J. Cell. Biochem.* **1994**, *55*, 1–11.
- 459 57. Arruda, A.P.; Hotamisligil, G.S. Calcium homeostasis and organelle function in the pathogenesis of
460 obesity and diabetes. *Cell Metab.* **2015**, *22*, 381–397.
- 461 58. Mungrue, I.N.; Pagnon, J.; Kohannim, O.; Gargalovic, P.S.; Lusa, A.J. CHAC1/MGC4504 is a novel
462 proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP
463 cascade. *J. Immunol.* **2009**, *182*, 466–476.
- 464 59. Wang, Y.; Wan, B.; Li, D.; Zhou, J.; Li, R.; Bai, M.; Chen, F.; Yu, L. BRSK2 is regulated by ER stress in
465 protein level and involved in ER stress-induced apoptosis. *Biochem. Biophys. Res. Commun.* **2012**, *423*,
466 813–818.
- 467 60. Schröder, M.; Kaufman, R.J. ER stress and the unfolded protein response. *Mutat. Res. - Fundam. Mol.*
468 *Mech. Mutagen.* **2005**, *569*, 29–63.
- 469 61. Volmer, R.; Ron, D. Lipid-dependent regulation of the unfolded protein response. *Curr. Opin. Cell Biol.*
470 **2015**, *33*, 67–73.
- 471 62. Eizirik, D.L.; Cardozo, A.K.; Cnop, M. The role for endoplasmic reticulum stress in diabetes mellitus.
472 *Endocr. Rev.* **2008**, *29*, 42–61.
- 473 63. Basseri, S.; Austin, R.C. Endoplasmic reticulum stress and lipid metabolism: Mechanisms and
474 therapeutic potential. *Biochem. Res. Int.* **2012**, *2012*.
- 475 64. Cnop, M.; Foufelle, F.; Velloso, L.A. Endoplasmic reticulum stress, obesity and diabetes. *Trends Mol. Med.*
476 **2012**, *18*, 59–68.
- 477 65. Zmuda, E.J.; Qi, L.; Zhu, M.X.; Mirmira, R.G.; Montminy, M.R.; Hai, T. The roles of ATF3, an adaptive-
478 response gene, in high-fat-diet-induced diabetes and pancreatic β -cell dysfunction. *Mol. Endocrinol.* **2010**,
479 *24*, 1423–1433.
- 480 66. Aung, H.H.; Lame, M.W.; Gohil, K.; An, C. II; Wilson, D.W.; Rutledge, J.C. Induction of ATF3 gene
481 network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and
482 inflammation. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 2088–2096.
- 483 67. Jang, M.K.; Son, Y.; Jung, M.H. ATF3 plays a role in adipocyte hypoxia-mediated mitochondria
484 dysfunction in obesity. *Biochem. Biophys. Res. Commun.* **2013**, *431*, 421–427.
- 485 68. Kalfon, R.; Koren, L.; Aviram, S.; Schwartz, O.; Hai, T.; Aronheim, A. ATF3 expression in cardiomyocytes
486 preserves homeostasis in the heart and controls peripheral glucose tolerance. *Cardiovasc. Res.* **2017**, *113*,
487 134–146.
- 488 69. Kim, J.Y.; Park, K.J.; Hwang, J.Y.; Kim, G.H.; Lee, D.Y.; Lee, Y.J.; Song, E.H.; Yoo, M.G.; Kim, B.J.; Suh,
489 Y.H.; et al. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired
490 glucose homeostasis. *J. Hepatol.* **2017**, *67*, 349–359.
- 491 70. Kim, S.; Song, N.J.; Bahn, G.; Chang, S.H.; Yun, U.J.; Ku, J.M.; Jo, D.G.; Park, K.W. Atf3 induction is a
492 therapeutic target for obesity and metabolic diseases. *Biochem. Biophys. Res. Commun.* **2018**, *504*, 903–908.
- 493 71. Hyun, B.K.; Kong, M.; Tae, M.K.; Young, H.S.; Kim, W.H.; Joo, H.L.; Ji, H.S.; Myeong, H.J. NFATc4 and
494 ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. *Diabetes* **2006**, *55*, 1342–
495 1352.
- 496 72. Rasouli, N.; Molavi, B.; Elbein, S.C.; Kern, P.A. Ectopic fat accumulation and metabolic syndrome.

- 497 *Diabetes, Obes. Metab.* **2007**, *9*, 1–10.
- 498 73. Zerega, B.; Camardella, L.; Cermelli, S.; Sala, R.; Cancedda, R.; Descalzi Cancedda, F. Avidin expression
499 during chick chondrocyte and myoblast development in vitro and in vivo: regulation of cell
500 proliferation. *J Cell Sci* **2001**, *114*, 1473–1482.
- 501 74. Mead, J.R.; Irvine, S.A.; Ramji, D.P. Lipoprotein lipase: Structure, function, regulation, and role in
502 disease. *J. Mol. Med.* **2002**, *80*, 753–769.
- 503 75. Wang, H.; Eckel, R.H. Lipoprotein lipase: from gene to obesity. *Am. J. Physiol. Metab.* **2009**, *297*, E271–
504 E288.
- 505 76. Bonen, A.; Parolin, M.L.; Steinberg, G.R.; Calles-Escandon, J.; Tandon, N.N.; Glatz, J.F.C.; Luiken, J.J.F.P.;
506 Heigenhauser, G.J.F.; Dyck, D.J. Triacylglycerol accumulation in human obesity and type 2 diabetes is
507 associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal
508 FAT/CD36. *FASEB J.* **2004**, *18*, 1144–1146.
- 509 77. Zizola, C.F.; Schwartz, G.J.; Vogel, S. Cellular retinol-binding protein type III is a PPAR γ target gene and
510 plays a role in lipid metabolism. *Am. J. Physiol. Metab.* **2008**, *295*, E1358–E1368.
- 511 78. Puri, V.; Ranjit, S.; Konda, S.; Nicoloso, S.M.C.; Straubhaar, J.; Chawla, A.; Chouinard, M.; Lin, C.;
512 Burkart, A.; Corvera, S.; et al. Cidea is associated with lipid droplets and insulin sensitivity in humans.
513 *Proc. Natl. Acad. Sci.* **2008**, *105*, 7833–7838.
- 514 79. Martin, S.; Parton, R.G. Characterization of Rab18, a lipid droplet-associated Small GTPase. In *Methods*
515 *in Enzymology*; 2008; Vol. 438, pp. 109–129 ISBN 9780123739681.
- 516 80. Green, C.R.; Wallace, M.; Divakaruni, A.S.; Phillips, S.A.; Murphy, A.N.; Ciaraldi, T.P.; Metallo, C.M.
517 Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis. *Nat. Chem. Biol.*
518 **2016**, *12*, 15–21.
- 519 81. Rutsch, F.; Gailus, S.; Suormala, T.; Fowler, B. LMBRD1: The gene for the cblF defect of vitamin B12
520 metabolism. *J. Inherit. Metab. Dis.* **2011**, *34*, 121–126.
- 521 82. Szatmari, I.; Töröcsik, D.; Agostini, M.; Nagy, T.; Gurnell, M.; Barta, E.; Chatterjee, K.; Nagy, L. PPAR γ
522 regulates the function of human dendritic cells primarily by altering lipid metabolism. *Blood* **2007**, *110*,
523 3271–3280.
- 524 83. Turcot, V.; Lu, Y.; Highland, H.M.; Schurmann, C.; Justice, A.E.; Fine, R.S.; Bradfield, J.P.; Esko, T.; Giri,
525 A.; Graff, M.; et al. Protein-altering variants associated with body mass index implicate pathways that
526 control energy intake and expenditure in obesity. *Nat. Genet.* **2018**, *50*, 26–35.
- 527 84. Hong-yan, S.H.I.; Qi, H.E.; Min, C.; Ying-ning, S.U.N.; Hui, L.I.; Ning, W. Effect of HOPX gene
528 overexpression on chicken preadipocyte proliferation. **2015**, *48*, 1624–1631.
- 529 85. Zhang, K.; Zhang, Z.W.; Wang, W.S.; Yan, X.H.; Li, H.; Wang, N. Cloning and expression of chicken
530 HOPX gene. *J. Northeast Agric. Univ.* **2012**, *43*, 46–53.
- 531 86. Chen, Z.; Zhao, T.-J.; Li, J.; Gao, Y.-S.; Meng, F.-G.; Yan, Y.-B.; Zhou, H.-M. Slow skeletal muscle myosin-
532 binding protein-C (MyBPC1) mediates recruitment of muscle-type creatine kinase (CK) to myosin.
533 *Biochem. J.* **2011**, *436*, 437–445.
- 534 87. Liu, M.; Bai, J.; He, S.; Villarreal, R.; Hu, D.; Zhang, C.; Yang, X.; Liang, H.; Slaga, T.J.; Yu, Y.; et al. Grb10
535 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1.
536 *Cell Metab.* **2014**, *19*, 967–980.
- 537 88. Van Leeuwen, E.M.; Karssen, L.C.; Deelen, J.; Isaacs, A.; Medina-Gomez, C.; Mbarek, H.; Kanterakis, A.;
538 Trompet, S.; Postmus, I.; Verweij, N.; et al. Genome of the Netherlands population-specific imputations
539 identify an ABCA6 variant associated with cholesterol levels. *Nat. Commun.* **2015**, *6*.

- 540 89. Kilpeläinen, T.O.; Bentley, A.R.; Noordam, R.; Sung, Y.J.; Schwander, K.; Winkler, T.W.; Jakupović, H.;
541 Chasman, D.I.; Manning, A.; Ntalla, I.; et al. Multi-ancestry study of blood lipid levels identifies four loci
542 interacting with physical activity. *Nat. Commun.* **2019**, *10*.
- 543 90. Willer, C.J.; Schmidt, E.M.; Sengupta, S.; Peloso, G.M.; Gustafsson, S.; Kanoni, S.; Ganna, A.; Chen, J.;
544 Buchkovich, M.L.; Mora, S.; et al. Discovery and refinement of loci associated with lipid levels. *Nat.*
545 *Genet.* **2013**, *45*, 1274–1285.
- 546 91. Surakka, I.; Horikoshi, M.; Mägi, R.; Sarin, A.-P.; Mahajan, A.; Lagou, V.; Marullo, L.; Ferreira, T.;
547 Miraglio, B.; Timonen, S.; et al. The impact of low-frequency and rare variants on lipid levels. *Nat. Genet.*
548 **2015**, *47*, 589–597.
- 549 92. Forsythe, E.; Beales, P.L. Bardet-Biedl syndrome. *Eur. J. Hum. Genet.* **2013**, *21*, 8–13.
- 550 93. Heuckeroth, R.O.; Birkenmeier, E.H.; Levin, M.S.; Gordon, J.I. Analysis of the tissue-specific expression,
551 developmental regulation, and linkage relationships of a rodent gene encoding heart fatty acid binding
552 protein. *J. Biol. Chem.* **1987**, *262*, 9709–9717.
- 553 94. Puig-Oliveras, A.; Ramayo-Caldas, Y.; Corominas, J.; Estellé, J.; Pérez-Montarelo, D.; Hudson, N.J.;
554 Casellas, J.; Ballester, J.M.F.M. Differences in muscle transcriptome among pigs phenotypically extreme
555 for fatty acid composition. *PLoS One* **2014**, *9*.
- 556 95. Resnyk, C.W.; Carré, W.; Wang, X.; Porter, T.E.; Simon, J.; Le Bihan-Duval, E.; Duclos, M.J.; Aggrey, S.E.;
557 Cogburn, L.A. Transcriptional analysis of abdominal fat in chickens divergently selected on bodyweight
558 at two ages reveals novel mechanisms controlling adiposity: Validating visceral adipose tissue as a
559 dynamic endocrine and metabolic organ. *BMC Genomics* **2017**, *18*, 1–31.
- 560 96. Lefterova, M.I.; Zhang, Y.; Steger, D.J.; Schupp, M.; Schug, J.; Cristancho, A.; Feng, D.; Zhuo, D.;
561 Stoeckert, C.J.; Liu, X.S.; et al. PPAR γ and C/EBP factors orchestrate adipocyte biology via adjacent
562 binding on a genome-wide scale. *Genes Dev.* **2008**, *22*, 2941–2952.
- 563 97. Laplante, M.; Sell, H.; MacNaul, K.L.; Richard, D.; Berger, J.P.; Deshaies, Y. PPAR-gamma activation
564 mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity. *Diabetes* **2003**,
565 *52*, 291–299.
- 566 98. Semple, R.K.; Chatterjee, V.K.K.; Rahilly, S.O. PPAR γ and human metabolic disease. *J. Clin. Invest.* **2006**,
567 *116*, 581–589.
- 568 99. Phua, W.W.T.; Wong, M.X.Y.; Liao, Z.; Tan, N.S. An apparent functional consequence in skeletal muscle
569 physiology via peroxisome proliferator-activated receptors. *Int. J. Mol. Sci.* **2018**, *19*.
- 570 100. Wang, Y.X. PPARs: Diverse regulators in energy metabolism and metabolic diseases. *Cell Res.* **2010**, *20*,
571 124–137.
- 572 101. Mitch, W.E.; Medina, R.; Griebler, S.; May, R.C.; England, B.K.; Price, S.R.; Bailey, J.L.; Goldberg, A.L.
573 Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-
574 dependent pathway involving ubiquitin and proteasomes. *J. Clin. Invest.* **1994**, *93*, 2127–2133.
- 575 102. Medina-Gomez, G.; Gray, S.; Vidal-Puig, A. Adipogenesis and lipotoxicity: Role of peroxisome
576 proliferator-activated receptor γ (PPAR γ) and PPAR γ coactivator-1 (PGC1). *Public Health Nutr.* **2007**, *10*,
577 1132–1137.
- 578 103. Dammone, G.; Karaz, S.; Lukjanenko, L.; Winkler, C.; Sizzano, F.; Jacot, G.; Migliavacca, E.; Palini, A.;
579 Desvergne, B.; Gilardi, F.; et al. PPAR γ Controls Ectopic Adipogenesis and Cross-Talks with Myogenesis
580 During Skeletal Muscle Regeneration. *Int. J. Mol. Sci.* **2018**, *19*, 2044.
- 581 104. Wang, Y.H.; Byrne, K.A.; Reverter, A.; Harper, G.S.; Taniguchi, M.; McWilliam, S.M.; Mannen, H.;
582 Oyama, K.; Lehnert, S.A. Transcriptional profiling of skeletal muscle tissue from two breeds of cattle.

- 583 *Mamm. Genome* **2005**, *16*, 201–210.
- 584 105. Jeong, J.; Kwon, E.G.; Im, S.K.; Seo, K.S.; Baik, M. Expression of fat deposition and fat removal genes is
585 associated with intramuscular fat content in longissimus dorsi muscle of Korean cattle steers. *J. Anim.*
586 *Sci.* **2012**, *90*, 2044–2053.
- 587 106. Cui, H.; Zheng, M.; Zhao, G.; Liu, R.; Wen, J. Identification of differentially expressed genes and
588 pathways for intramuscular fat metabolism between breast and thigh tissues of chickens. *BMC Genomics*
589 **2018**, *19*, 1–9.
- 590 107. Liu, L.; Cui, H.; Fu, R.; Zheng, M.; Liu, R.; Zhao, G.; Wen, J. The regulation of IMF deposition in pectoralis
591 major of fast- and slow- growing chickens at hatching. *J. Anim. Sci. Biotechnol.* **2017**, *8*, 1–8.
- 592 108. Kee, H.J.; Kim, J.R.; Nam, K. Il; Hye, Y.P.; Shin, S.; Jeong, C.K.; Shimono, Y.; Takahashi, M.; Myung, H.J.;
593 Kim, N.; et al. Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces
594 skeletal muscle differentiation. *J. Biol. Chem.* **2007**, *282*, 7700–7709.
- 595 109. Shin, C.H.; Liu, Z.P.; Passier, R.; Zhang, C.L.; Wang, D.Z.; Harris, T.M.; Yamagishi, H.; Richardson, J.A.;
596 Childs, G.; Olson, E.N. Modulation of cardiac growth and development by HOP, an unusual
597 homeodomain protein. *Cell* **2002**, *110*, 725–735.
- 598 110. Kojic, S.; Nestorovic, A.; Rakicevic, L.; Belgrano, A.; Stankovic, M.; Divac, A.; Faulkner, G. A novel role
599 for cardiac ankyrin repeat protein Ankrd1/CARP as a co-activator of the p53 tumor suppressor protein.
600 *Arch. Biochem. Biophys.* **2010**, *502*, 60–67.
- 601 111. Yang, W.; Zhang, Y.; Ma, G.; Zhao, X.; Chen, Y.; Zhu, D. Identification of gene expression modifications
602 in myostatin-stimulated myoblasts. *Biochem. Biophys. Res. Commun.* **2005**, *326*, 660–666.
- 603 112. Ma, G.; Wang, H.; Gu, X.; Li, W.; Zhang, X.; Cui, L.; Li, Y.; Zhang, Y.; Zhao, B.; Li, K. CARP, a myostatin-
604 downregulated gene in CFM cells, is a novel essential positive regulator of myogenesis. *Int. J. Biol. Sci.*
605 **2014**, *10*, 309–320.
- 606 113. Bagnall, R.D.; Yeates, L.; Semsarian, C. Analysis of the Z-disc genes PDLIM3 and MYPN in Patients with
607 Hypertrophic Cardiomyopathy. *Int. J. Cardiol.* **2010**, *145*, 601–602.
- 608 114. Eftestøl, E.; Norman Alver, T.; Gundersen, K.; Bruusgaard, J.C. Overexpression of SMPX in adult skeletal
609 muscle does not change skeletal muscle fiber type or size. *PLoS One* **2014**, *9*.
- 610 115. Kostek, M.C.; Chen, Y.-W.; Cuthbertson, D.J.; Shi, R.; Fedele, M.J.; Esser, K.A.; Rennie, M.J. Gene
611 expression responses over 24 h to lengthening and shortening contractions in human muscle: major
612 changes in CSRP3, MUSTN1, SIX1, and FBXO32. *Physiol. Genomics* **2007**, *31*, 42–52.
- 613 116. Barash, I.A.; Mathew, L.; Ryan, A.F.; Chen, J.; Lieber, R.L. Rapid muscle-specific gene expression changes
614 after a single bout of eccentric contractions in the mouse. *Am. J. Physiol. Physiol.* **2004**, *286*, C355–C364.
- 615 117. Chen, Y.W.; Nader, G.A.; Baar, K.R.; Fedele, M.J.; Hoffman, E.P.; Esser, K.A. Response of rat muscle to
616 acute resistance exercise defined by transcriptional and translational profiling. *J. Physiol.* **2002**, *545*, 27–
617 41.
- 618 118. Kemp, T.J.; Sadusky, T.J.; Simon, M.; Brown, R.; Eastwood, M.; Sassoon, D.A.; Coulton, G.R.
619 Identification of a novel stretch-responsive skeletal muscle gene (Smpx). *Genomics* **2001**, *72*, 260–271.
- 620 119. MacRae, V.E.; Mahon, M.; Gilpin, S.; Sandercock, D.A.; Mitchell, M.A. Skeletal muscle fibre growth and
621 growth associated myopathy in the domestic chicken (*Gallus domesticus*). *Br. Poult. Sci.* **2006**, *47*, 264–
622 272.
- 623 120. Kuttappan, V.A.; Shivaprasad, H. I.; Shaw, D.P.; Valentine, B.A.; Hargis, B.M.; Clark, F.D.; McKee, S.R.;
624 Owens, C.M. Pathological changes associated with white striping in broiler breast muscles. *Poult. Sci.*
625 **2013**, *92*, 331–338.

- 626 121. Lilburn, M.S.; Griffin, J.R.; Wick, M. From muscle to food: oxidative challenges and developmental
627 anomalies in poultry breast muscle. *Poult. Sci.* **2018**.
- 628 122. Satriano, J. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. *Amino*
629 *Acids* **2007**, *33*, 331–339.
- 630 123. Sharma, V.; McNeill, J.H. Diabetic cardiomyopathy: Where are we 40 years later? *Can. J. Cardiol.* **2006**, *22*,
631 305–308.
- 632 124. Liang, W.; Menke, A.L.; Driessen, A.; Koek, G.H.; Lindeman, J.H.; Stoop, R.; Havekes, L.M.; Kleemann,
633 R.; Van Den Hoek, A.M. Establishment of a general NAFLD scoring system for rodent models and
634 comparison to human liver pathology. *PLoS One* **2014**, *9*, 1–17.
- 635 125. Jingting, S.; Qin, X.; Yanju, S.; Ming, Z.; Yunjie, T.; Gaige, J.; Zhongwei, S.; Jianmin, Z. Oxidative and
636 glycolytic skeletal muscles show marked differences in gene expression profile in Chinese Qingyuan
637 partridge chickens. *PLoS One* **2017**, *12*, 1–17.
- 638 126. Palmer, S.; Groves, N.; Schindeler, A.; Yeoh, T.; Biben, C.; Wang, C.-C.; Sparrow, D.B.; Barnett, L.;
639 Jenkins, N.A.; Copeland, N.G.; et al. The Small Muscle-specific Protein Csl Modifies Cell Shape and
640 Promotes Myocyte Fusion in an... *J. Cell Biol.* **2001**, *153*, 985.
- 641 127. Tsukada, T.; Pappas, C.T.; Moroz, N.; Antin, P.B.; Kostyukova, A.S.; Gregorio, C.C. Leiomodin-2 is an
642 antagonist of tropomodulin-1 at the pointed end of the thin filaments in cardiac muscle. *J. Cell Sci.* **2010**,
643 *123*, 3136–3145.
- 644 128. Pappas, C.T.; Farman, G.P.; Mayfield, R.M.; Konhilas, J.P.; Gregorio, C.C. Cardiac-specific knockout of
645 Lmod2 results in a severe reduction in myofilament force production and rapid cardiac failure. *J. Mol.*
646 *Cell. Cardiol.* **2018**, *122*, 88–97.
- 647 129. Aihara, Y.; Kurabayashi, M.; Saito, Y.; Ohyama, Y.; Tanaka, T.; Takeda, S.; Tomaru, K.; Sekiguchi, K.;
648 Arai, M.; Nakamura, T.; et al. Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy:
649 Role of M-CAT element within the promoter. *Hypertension* **2000**, *36*, 48–53.
- 650